<DOC>
	<DOC>NCT00961038</DOC>
	<brief_summary>Objectives of the study are to investigate the safety, tolerability and levels of ciprofloxacin in the lung after single and multiple inhalative administration to patients with moderate to severe COPD (stage II-III according to GOLD Criteria)</brief_summary>
	<brief_title>Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Adult patients with COPD, 40 to 75 years of age Diagnosis of COPD Airway obstruction with a postbronchodilator Forced Expiratory Volume (FEV1) of &gt;/=30% and &lt;/=65% of predicted and a postbronchodilator FEV1 / Forced Vital Capacity (FVC) of &lt;/=70% Current or exsmokers with a smoking history of more than 10 packyears Patients must be able to produce acceptable induced sputum samples (as defined in the Study Procedure Manual) Normal body weight: Body Mass Index (BMI) between 19 and 35 kg/m2 Significant respiratory disease other than COPD as bronchial asthma, Cystic fibrosis or clinically evident bronchiectasis More than one COPD exacerbation within 12 months and within 8 weeks prior to screening total blood eosinophil count &gt;/=600/mm3 Thoracotomy with pulmonary resection Regularly use of daytime oxygen therapy for more than one hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy during clinic visits Hypersensitivity to the investigational drug or to other quinolones and/or to inactive constituents of the inhalation powder Hypersensitivity of the bronchial system to inhalation of nebulized drugs or saline solution Patients with a history of severe allergies, nonallergic drug reactions, or multiple drug allergies Concomitant use of medication which could interfere with the investigational drug. Before study drug administration a wash out period of more than 5 half lives has to be considered Concomitant inhalative therapy with antibiotics and/or concomitant systemic therapy with fluoroquinolones Oral betaandrenergics, beta blockers oral steroids Methylxanthines: 24hour washout of shortacting theophylline and 48hour washout of longacting theophylline prior to prestudy examination Antihistamines, antileukotrienes prescribed for asthma oral cromolyn sodium or oral nedocromil sodium</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Ciprofloxacin</keyword>
	<keyword>Inhalation</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>COPD</keyword>
</DOC>